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Aims Cathepsin D is a ubiquitous lysosomal protease that is primarily secreted due to oxidative stress. The role of
circulating cathepsin D in heart failure (HF) is unknown. The aim of this study is to determine the association between
circulating cathepsin D levels and clinical outcomes in patients with HF and to investigate the biological settings that
induce the release of cathepsin D in HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Cathepsin D levels were studied in 2174 patients with HF from the BIOSTAT-CHF index study. Results were validated
in 1700 HF patients from the BIOSTAT-CHF validation cohort. The primary combined outcome was all-cause
mortality and/or HF hospitalizations. Human pluripotent stem cell-derived cardiomyocytes were subjected to hypoxic,
pro-inflammatory signalling and stretch conditions. Additionally, cathepsin D expression was inhibited by targeted
short hairpin RNAs (shRNA). Higher levels of cathepsin D were independently associated with diabetes mellitus, renal
failure and higher levels of interleukin-6 and N-terminal pro-B-type natriuretic peptide (P< 0.001 for all). Cathepsin D
levels were independently associated with the primary combined outcome [hazard ratio (HR) per standard deviation
(SD): 1.12; 95% confidence interval (CI) 1.02–1.23], which was validated in an independent cohort (HR per SD:
1.23, 95% CI 1.09–1.40). In vitro experiments demonstrated that human stem cell-derived cardiomyocytes released
cathepsin D and troponin T in response to mechanical stretch. ShRNA-mediated silencing of cathepsin D resulted in
increased necrosis, abrogated autophagy, increased stress-induced metabolism, and increased release of troponin T
from human stem cell-derived cardiomyocytes under stress.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions Circulating cathepsin D levels are associated with HF severity and poorer outcome, and reduced levels of cathepsin
D may have detrimental effects with therapeutic potential in HF.
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Introduction
Oxidative stress is an important pathophysiological pathway in
the development and progression of heart failure (HF).1–3 Oxida-
tive stress occurs when the balance between production of reac-
tive oxygen species and endogenous antioxidative mechanisms
fails.1,4,5
The aspartyl protease cathepsin D is a ubiquitously expressed
lysosomal enzyme that is essential for protein degradation, prote-
olytic activation of hormones and growth factors, and is primarily
secreted following oxidative stress.6–8 Cathepsin D is a member
of the A1 family of peptidases and is composed of a light and a
heavy chain that together form the fully active mature enzyme.9,10
Recent data showed that cathepsin D was upregulated in a myocar-
dial infarction model. Furthermore, upregulating cathepsin D was
cardioprotective and prevented the development of HF.11,12 In addi-
tion, high circulating levels of cathepsin D are associated with
increased risk of coronary events and new-onset HF following
ST-segment elevation acute myocardial infarction.13,14 The cause
for cathepsin D release and whether levels of cathepsin D are
associated with clinical outcomes in the general HF population is
currently unknown.
Therefore, in the present study, we investigated the association
between circulating cathepsin D levels and clinical variables as well
as cardiovascular outcome. To assess what type of stress induces
cathepsin D release from cardiomyocytes, we measured extracellu-
lar cathepsin D levels from human stem cell-derived cardiomyocyte
(as a proxy for human cardiomyocytes in vivo) in human cardiac in
vitro models of ventricular wall stress, hypoxia (i.e. ischaemia) and
inflammation. Finally, we assessed how inhibition of intracellular
cathepsin D expression affects human stem cell-derived cardiomy-
ocyte survival after stress.
Methods
Patient population and study design
The current study was performed as a sub-study of the BIOlogy Study
to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF).15–18
In short, the BIOSTAT-CHF study includes two cohorts of patients
with HF. The index cohort consists of 2516 patients with HF from
69 centres in 11 European countries. Inclusion criteria for the index
cohort include: patients with ≥18 years of age, having symptoms of
new-onset or worsening HF, as confirmed by a left ventricular ejection
fraction (LVEF) of ≤40%. Additionally, patients with LVEF >40% were
enrolled in the BIOSTAT-CHF study, but were required to have a
B-type natriuretic peptide >400 pg/mL or an N-terminal pro-B-type
natriuretic peptide (NT-proBNP) >2000 pg/mL. Patients in the index
and validation cohort were required to be sub-optimally treated
on either angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers (ACEi/ARBs) and/or beta-blockers, or they
received ≤50% of ACEi/ARB and/or beta-blockers at the time of
inclusion and anticipated initiation/up-titration of ACEi/ARBs and
beta-blockers.
The validation cohort consists of 1738 patients from six cen-
tres in Scotland, UK. Patients were included if they were ≥18 years
of age, diagnosed with HF and were previously admitted with HF
requiring diuretic treatment. They were sub-optimally treated with ..
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.. ACEi/ARBs and/or beta-blockers, and anticipated initiation or uptitra-
tion of ACEi/ARBs and beta-blockers.
Study definitions and measurements
Medical history, medication use and physical examination were
recorded at baseline. Overall, 91% of patients in the index cohort had
echocardiography performed <6 months before inclusion. Changes
in ACEi/ARB and beta-blocker usage were recorded. HF with a
reduced ejection fraction (HFrEF) was defined as an LVEF ≤40%,
HF with a mid-range ejection fraction (HFmrEF) was defined as an
LVEF of 41–49%, and HF with a preserved ejection fraction (HFpEF)
was defined as an LVEF ≥50%. Co-morbidities were identified by
chart review from medical history, anaemia was defined accord-
ing to World Health Organization definitions with a sex specific
cutoff point for haemoglobin (<13 g/dL in males and <12 g/dL in
females).
Outcome
The primary outcome of this study was a combined outcome of
all-cause mortality and HF hospitalizations at 2 years. The secondary
outcome was all-cause mortality at 2 years. The cause of hospitalization
was determined by the individual site investigators.
Biomarkers
Circulating plasma levels were determined using the Olink Proseek®
Multiplex Cardiovascular III96x96 kit by the Olink Bioscience analysis
service (Uppsala, Sweden) as described previously.16,19,20 The kit is
based on the Proximity Extension Assay (PEA) technology that binds
oligonucleotide-labelled antibody probe pairs to the respective target
in the sample. Proseek® data are presented as arbitrary units (AU) for
normalized protein expression. The inter- and intra-assay coefficients
of variation are 6.6% and 10.3%, respectively. The lower limit of
detection was 976.6 pg/mL. Due to the nature of the measurement
using PEA technology, cathepsin Dwas expressed as relative AU, where
higher values correspond to higher levels of cathepsin D.
Cell culture and differentiation
HUES9 human pluripotent stem cells (hPSC; Harvard Stem Cell
Institute) were maintained and differentiated as published previously.21
Briefly, hPSC were maintained in Essential 8 medium (A1517001;
Thermo Fisher Scientific) before differentiation to stem cell-derived
cardiomyocytes (hPSC-CM) was initiated, which was achieved by
culturing hPSC in RPMI1640 medium (21875–034, Thermo Fisher
Scientific) supplemented with 1x B27 minus insulin (Thermo Fisher
Scientific) and 6 μmol/L CHIR99021 (13122, Cayman Chemical).
After 2 days, medium was refreshed with RPMI1640 supplemented
with 1x B27 minus insulin and 2 μmol/L Wnt-C59 (5148, Tocris Bio-
science). Again after 2 days, medium was changed to CDM3 medium
as described by Burridge et al.22 and was refreshed every other day.
On day 8 after induction of differentiation, spontaneously contracting
cardiomyocytes were observed, which were subsequently purified
by changing the medium to glucose-free CDM3 medium supple-
mented with 5mmol/L sodium DL-lactate (CDM3L; Sigma-Aldrich),
as published by Burridge et al.22 Ultimately, this resulted in >99%
pure spontaneously beating stem cell-derived cardiomyocyte
cultures.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Cardiomyocyte stimulation
Obtained human cardiomyocytes were seeded on a flexible surface
(BF-3001C, FlexCell) subjected to 15% equiaxial mechanical stretch
at 1 Hz for 24 h or 48 h using a FX-4000 system (FlexCell) as
mentioned previously.23 Cardiomyocytes were cultured in anaerobic
pouches (260 683, BD) for 72 h to create hypoxic conditions. Addition-
ally, cardiomyocytes were incubated with 100 ng/mL tumour necro-
sis factor alpha (TNF𝛼; SRP3177, Sigma-Aldrich) for 72 h in order
to mimic an inflammatory environment. To inhibit lysosomal exocy-
tosis, hPSC-CM were incubated with the small molecule vacuolin-1
(20 425, Cayman Chemical) at a concentration of 1 μM in the cell
medium.24
Lentivirus production
HEK-293 T cells were cultured at 37∘C and 5% CO2 until 70% con-
fluency was reached in Dulbecco modified Eagle medium (DMEM;
41 965–039, Thermo Fisher Scientific) supplemented with 10% fetal
calf serum (FCS; F7524, Sigma-Aldrich). HEK-293 T were transfected
with Fugene HD (E2311, Promega) and a mix of pCMV Δ8.91-transfer
plasmid, VSV-G-packaging plasmid and pLKO.1-plasmid expressing
short hairpin RNA (shRNA) against cathepsin D or a non-mammalian
scrambled sequence at a ratio of 5:2:6. Media were replaced with
fresh CDM3 medium after 24 h. CDM3 medium containing viral
particles was harvested and filtered with 0.45 nm Nalgene filter
after 48 h. Clean viral supernatant was used directly or was snap
frozen for extended storage. pLKO.1-shCTSD (TRCN0000003660,
Sigma-Aldrich) and pLKO.1-shSCR (SHC002, Sigma-Aldrich) were pur-
chased from Sigma MISSION RNAi.
Immunoblotting
Protein was isolated in radioimmunoprecipitation assay (RIPA)
buffer supplemented with 1% phosphatase inhibitor cocktail 3
(p0044, Sigma-Aldrich), 1x cOmplete protease inhibitor cocktail
(11 873 580 001, Roche), and 15mM sodium orthovanadate (S6508,
Sigma-Aldrich). Protein concentration was determined with the
DC protein assay kit. Equal amounts of protein were separated by
SDS-PAGE and proteins were transferred to PVDF membrane. For
detection of specific proteins, the following antibodies were used:
polyclonal anti-cathepsin D IgG (1:1000; sc-10 725, Santa Cruz), mon-
oclonal anti-Caspase 3 (1:1000; 9664, Cell Signalling) and monoclonal
anti-GAPDH IgG (1:30.000; 10R-G109A, Fitzgerald). After washing,
blots were incubated with polyclonal goat anti-rabbit IgG-HRP (1:2000;
P0448, Dako), and polyclonal rabbit anti-mouse IgG-HRP (1:2000;
P0260, Dako). Signals were detected visualized with enhanced chemi-
luminescence (ECL; NEL120001EA, PerkinElmer) and densitometry
has been analysed with ImageQuant LAS 4000 (GE Healthcare).
Cathepsin D signals were normalized to respective GAPDH
levels.
Cathepsin D and troponin T
determination in medium
Medium samples were collected and centrifuged at 12.000× g to
remove cellular debris. Cathepsin Dwas determined in the supernatant
by enzyme-linked immunosorbent assay (ELISA) according to manufac-
turer protocols (ab119586, Abcam). Troponin T levels were analysed
using an electrochemiluminescence immunoassay kit (0509277, Roche
Diagnostics). .
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. Immunocytochemistry and sarcomere
classification
Die-cut pieces of stretch plate membrane were washed twice with
cold PBS, and fixed with 4% paraformaldehyde on ice during 10 min.
Fixed cells were washed three times with PBS, followed by perme-
abilization with PBS+ 0.3% Triton-X100 (T9284, Sigma-Aldrich) on
ice during 5 min. Samples were blocked for 1 h at room temperature
with PBS/Tween (0.1%; P1379, Sigma-Aldrich) containing 3% BSA
(11 930, Serva) and 2% goat serum (G9023, Sigma). Cells were
subsequently incubated with monoclonal anti-𝛼-actinin IgG1 (1:100;
A7811, Sigma-Aldrich) dissolved in the blocking mix during 1 h. After
washing, cells were incubated with Alexa Fluor 555 goat-anti-mouse
IgG (1:1000; A21424, Thermo Fisher Scientific). Pieces of membrane
were mounted with Vectashield mounting medium containing DAPI
(H-1200, Vector labs) and images were obtained with a Leica AF-6000
microscope.
Sarcomere classification was determined as described previously.25
Briefly, images of hPSC-CM acquired after immunocytochemistry were
analysed based on three classes of sarcomeric structure: class I sarcom-
eres showed distinct sarcomeric bands (e.g. as stained positively for
𝛼-actinin) that cover >50% of the cell area. Class II sarcomeric struc-
ture showed clear sarcomeric bands, but covered <50% of the cell
area, while class III sarcomeres showed positive staining for 𝛼-actinin,
but lacked any band-like structures. Human PSC-CM were classified
based on sarcomere structure for each condition.
Apoptosis, necrosis, autophagy
and metabolism
Stem cell-derived cardiomyocyte survival (i.e. apoptosis and necro-
sis), levels of autophagy, and metabolic rates were determined with
the RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay kit
(JA1011, Promega), the CYTO-ID® Autophagy detection kit 2.0
(ENZ-KIT175-0050, Enzo Life Sciences), and the RealTime-Glo™ MT
Cell Viability Assay kit (G9711, Promega) respectively. All assays have
been performed according to respective manufacturer protocols on
living cells on pieces of flexible membrane that were die-cut from the
stretch plates.
Statistical analysis
Levels of cathepsin D in the BIOSTAT-CHF study were divided into
tertiles. Following, clinical characteristics between tertiles of cathepsin
D were compared using the one-way analysis of variance (ANOVA),
Kruskal–Wallis test or the Chi-square test where appropriate. Dis-
tribution of continuous data was visually inspected using Q–Q plots.
Logistic regression was used to investigate independent associations
with the highest tertile of cathepsin D. Differences in outcome were
graphically shown using Kaplan–Meier curves. The log-rank test was
used to test for difference in survival between tertiles of cathepsin
D. Cox regression analyses were used to investigate the linear asso-
ciation between cathepsin D and outcome. We corrected in a step-
wise manner for age, sex, body mass index, history of diabetes, and
usage of beta-blockers, ACEi and mineralocorticoid receptor antag-
onists at baseline. Additionally, we corrected for the BIOSTAT-CHF
risk engine, which has been published before.26 The BIOSTAT-CHF
risk model for predicting mortality included, age, blood urea nitro-
gen, NT-proBNP, haemoglobin and the use of a beta-blocker at time
of inclusion. The BIOSTAT-CHF risk model for predicting mortality or
HF hospitalization included age, NT-proBNP, haemoglobin, the use of a
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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beta-blocker at time of inclusion, a HF hospitalization in the year before
inclusion, peripheral oedema, systolic blood pressure, high-density
lipoprotein cholesterol, and sodium. Finally, to test whether cathep-
sin D improved this previous risk prediction model, we used Harrel’s
C index as well as the continuous net reclassification index and the
integrative discrimination increment.
Experimental (in vitro) groups consisted of at least three biolog-
ical replicates and technical duplicates were used. Data shown are
expressed as the mean± standard error of the mean. As data were con-
sidered to be non-parametrical, differences between two groups were
assessed by a Mann–Whitney U test, whereas comparisons between
three or more groups were assessed with a Kruskal–Wallis test fol-
lowed by Dunn’s post-hoc test. A P-value of< 0.05 was considered
statistically significant. Statistical analyses were performed using STATA
15.0 (College Station, TX, USA) and GraphPad Prism 7 (San Diego,
CA, USA).
Results
Patient characteristics
Baseline characteristics of patients from the BIOSTAT-CHF index
cohort according to tertiles of levels of cathepsin D are described
in Table 1. Patients with higher levels of cathepsin D were in a more
advanced New York Heart Association class, had worse signs and
symptoms, and more often a history of atrial fibrillation or diabetes
mellitus. Furthermore, patients with higher cathepsin D levels had
lower levels of total cholesterol and higher levels of NT-proBNP,
interleukin-6 and troponin T. In multivariable analyses, higher levels
of cathepsin D were independently associated with a history of
diabetes mellitus, higher levels of NT-proBNP, renin, and aspartate
aminotransferase (Table 2). Clinical characteristics are shown in
online supplementary Table S1 according to tertiles of cathepsin
D in the validation cohort.
Outcome analyses
Median follow-up was after 21months. In the BIOSTAT-CHF
index cohort, 855 patients died or were hospitalized for HF (40%).
The highest tertile of cathepsin D was associated with the highest
rates of the primary combined outcome (Figure 1A) or all-cause
mortality alone (Figure 1B). In multivariable analyses, higher levels
of cathepsin D were independently associated with the primary
combined outcome [hazard ratio (HR) 1.30; 95% confidence inter-
val (CI) 1.19–1.43; P< 0.001] and all-cause mortality alone (HR
1.40; 95% CI 1.24–1.58; P< 0.001) (Table 2). When correcting
for the BIOSTAT-CHF risk engine, higher levels of cathepsin D
were independently associated with the combined outcome (HR
1.12; 95% CI 1.02–1.23; P = 0.016) and all-cause mortality alone
(HR 1.15; 95% CI 1.01–1.29; P = 0.028) (Table 3). After further
correcting for a history of diabetes, higher levels of cathepsin
D remained significantly associated with the primary combined
outcome (HR 1.15; 95% CI 1.02–1.30; P = 0.022). Similar to the
index cohort, higher levels of cathepsin D showed an independent
association with mortality (HR 1.47; 95% CI 1.27–1.69; P< 0.001)
and the combined outcome in the validation cohort (HR 1.23; 95%
CI 1.09–1.40; P< 0.001) when corrected for the BIOSTAT-CHF
risk engine. ..
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cardiomyocytes released cathepsin D
in response to stretch
To determine which stress-inducing conditions could induce
cathepsin D release from hPSC-CM, we initially determined the
effects of neurohormonal stimulation (as is similar in HF con-
ditions) by incubating these hPSC-CM with incremental doses
of angiotensin II, isoproterenol, and norepinephrine (online sup-
plementary Figure S1). However, none of these stimuli induced
cathepsin D release at physiological concentrations. In contrast,
mechanical stretch and hypoxia resulted in increased levels of
cathepsin D in the cell medium, while TNF𝛼 did not elicit any
change in extracellular cathepsin D levels (Figure 2A). Strikingly,
only hypoxia reduced intracellular levels of cathepsin D, while
other conditions did not elicit any changes in intracellular cathep-
sin D (Figure 2B). To assess the relationship between extracellular
cathepsin D levels and hPSC-CM death, the cardiac damage marker
troponin T was quantified in the cell medium. Troponin T levels
were found to be elevated after mechanical stretch, while troponin
T levels were not significantly changed after TNF𝛼 stimulation or
hypoxia compared to controls (Figure 2C).
Reduced cathepsin D expression resulted
in impaired human stem cell-derived
cardiomyocyte survival and sarcomeric
structure
To assess the effects of reduced cathepsin D expression in response
to stress, we applied shRNA-mediated targeted cathepsin D knock-
down in hPSC-CM. We continued with the cyclic mechanical
stretch model as it induced increased cathepsin D release in vitro
and it has been extensively characterized as a representative model
for wall stress leading to cardiac hypertrophy.23 Viral RNA inter-
ference of cathepsin D resulted in an 88% reduction of intracel-
lular cathepsin D protein levels compared to scrambled control
hPSC-CM (shSCR; Figure 3A). Consequently, cathepsin D knock-
down resulted in significantly reduced cathepsin D release from
stretched hPSC-CM compared to stretched control hPSC-CM
(Figure 3B). Cathepsin D knockdown resulted in increased troponin
T levels in the medium of static hPSC-CM, which was exacer-
bated markedly after mechanical stretch (Figure 3C). We performed
immunocytochemistry to morphologically assess hPSC-CM mor-
phology based on sarcomeric structure, which also provided
indications about how muscle fibres were affected in stretched
hPSC-CM with and without cathepsin D silencing. To that end, we
stained hPSC-CM for 𝛼-actinin and determined the ratio of sarcom-
eric structures based on three cardiomyocyte classes (Figure 3D
and online supplementary Figure S2). We observed that knock-
down of cathepsin D resulted in deterioration of sarcomeres
independently of mechanical stretch. To determine the effects of
cathepsin D knockdown on cell death, we measured the levels
of apoptosis and necrosis (Figure 3E and 3F). Silencing of cathep-
sin D did not affect apoptosis, whereas necrosis was significantly
increased after hPSC-CM with cathepsin D knockdown have been
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of patients from the BIOSTAT-CHF index cohort according to tertiles of cathepsin D
1st tertile 2nd tertile 3rd tertile P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n 725 725 724
Demographics
Age (years) 68.4 (12.2) 68.7 (11.8) 69.6 (12.2) 0.140
Female sex 213 (29.4%) 170 (23.4%) 198 (27.3%) 0.035
HF type
HFrEF 538 (80.3%) 531 (81.4%) 503 (80.6%) 0.910
HFmrEF 85 (12.7%) 82 (12.6%) 76 (12.2%)
HFpEF 47 (7.0%) 39 (6.0%) 45 (7.2%)
BMI (kg/m2) 27.4 (5.4) 27.9 (5.4) 28.2 (5.7) 0.030
Ischaemic aetiology 306 (42.9%) 308 (43.6%) 337 (47.1%) 0.220
NYHA class
I 75 (10.3%) 59 (8.1%) 51 (7.0%) 0.028
II 356 (49.1%) 337 (46.5%) 310 (42.8%)
III 178 (24.6%) 209 (28.8%) 236 (32.6%)
IV 23 (3.2%) 23 (3.2%) 29 (4.0%)
NA 93 (12.8%) 97 (13.4%) 98 (13.5%)
Systolic BP (mmHg) 125.1 (23.0) 124.1 (20.9) 124.3 (22.1) 0.640
Diastolic BP (mmHg) 74.9 (13.3) 75.2 (13.2) 74.0 (13.4) 0.190
LVEF (%) 31.5 (10.6) 30.7 (10.7) 31.1 (11.0) 0.450
Heart rate (bpm) 77.8 (18.3) 80.6 (20.8) 81.9 (19.5) <0.001
Signs and symptoms
Peripheral oedema
Not present 287 (49.0%) 244 (41.6%) 202 (32.1%) <0.001
Ankle 167 (28.5%) 189 (32.2%) 174 (27.7%)
Below knee 105 (17.9%) 128 (21.8%) 174 (27.7%)
Above knee 27 (4.6%) 26 (4.4%) 79 (12.6%)
Elevated JVP 133 (25.7%) 140 (28.1%) 220 (41.3%) <0.001
Hepatomegaly 89 (12.3%) 76 (10.5%) 137 (19.1%) <0.001
Orthopnoea 197 (27.2%) 259 (35.8%) 298 (41.3%) <0.001
Medical history
Anaemia 244 (34.9%) 236 (34.3%) 279 (39.6%) 0.074
Atrial fibrillation 298 (41.1%) 348 (48.0%) 345 (47.7%) 0.012
Diabetes mellitus 198 (27.3%) 234 (32.3%) 269 (37.2%) <0.001
COPD 107 (14.8%) 137 (18.9%) 129 (17.8%) 0.095
Hypertension 447 (61.7%) 452 (62.3%) 448 (61.9%) 0.960
PAVD 77 (10.6%) 79 (10.9%) 84 (11.6%) 0.830
Stroke 69 (9.5%) 57 (7.9%) 79 (10.9%) 0.140
PCI 143 (19.7%) 143 (19.7%) 163 (22.5%) 0.320
Medication
Loop diuretics 719 (99.2%) 723 (99.7%) 721 (99.6%) 0.310
ACEi/ARB at baseline 528 (72.8%) 529 (73.0%) 502 (69.3%) 0.220
Beta-blocker at baseline 609 (84.0%) 603 (83.2%) 595 (82.2%) 0.650
Aldosterone antagonist 382 (52.7%) 399 (55.0%) 361 (49.9%) 0.140
Laboratory
Haemoglobin (g/dL) 13.2 (1.8) 13.3 (1.9) 13.1 (2.0) 0.038
Total cholesterol (mmol/L) 4.3 (3.5, 5.1) 4.2 (3.4, 5.1) 3.8 (3.1, 4.9) <0.001
IL-6 (pg/mL) 4 (2.4, 7.4) 5.1 (2.7, 9.5) 7.2 (4, 15.4) <0.001
eGFR (mL/min/1.73m2) 64 (50, 80) 63 (47, 78) 57 (42, 76) <0.001
Creatinine (μmol/L) 99 (81122) 104 (85, 129) 106 (87, 141) <0.001
Sodium (mmol/L) 140.0 (138.0, 142.0) 140.0 (137.0, 142.0) 139.0 (136.0, 141.0) <0.001
Potassium (mmol/L) 4.3 (3.9, 4.6) 4.3 (3.9, 4.6) 4.2 (3.9, 4.6) 0.014
HbA1c (%) 6.2 (5.6, 6.8) 6.2 (5.8, 7.2) 6.6 (5.9, 7.5) 0.006
NT-proBNP (ng/L) 3576.5 (2015.0, 7000.0) 3763.0 (2110.0, 7520.0) 5040.0 (2921.5, 9782.5) <0.001
Troponin I (μg/L) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.012
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IL-6, interleukin-6; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; NA, not
available; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PAVD, peripheral arterial vascular disease; PCI, percutaneous coronary
intervention.
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Table 2 Clinical characteristics and laboratory values
associated with cathepsin D
Univariable Multivariable
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Beta P-value Beta P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 0.06 0.003 0.03 0.531
Sex 0.01 0.545
BMI 0.06 0.004 0.10 0.013
Atrial fibrillation 0.08 <0.001 0.03 0.484
Hypertension −0.02 0.316
Diabetes 0.08 <0.001 0.08 0.049
eGFR −0.09 <0.001 −0.08 0.059
NT-proBNP 0.15 <0.001 0.11 0.014
Aldosterone 0.01 0.786
Renin 0.07 0.001 0.08 0.037
AST 0.20 <0.001 0.27 <0.001
ALT 0.09 0.001 −0.10 0.086
CRP 0.16 <0.001 0.05 0.236
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass
index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate;
NT-proBNP, N-terminal pro-B-type natriuretic peptide;
mechanically stretched. Additionally, we observed that stretched
hPSC-CM showed induction of autophagy, which was impaired in
hPSC-CM with cathepsin D knockdown (Figure 3G). Furthermore,
metabolism was found to be increased in stretched hPSC-CM with
cathepsin D knockdown exclusively (Figure 3H).
Cathepsin D retention improved
stretch-induced autophagy
To determine whether cathepsin D is actively secreted (i.e. exo-
cytosis) or passively released (i.e. loss of membrane integrity) by
stressed hPSC-CM, we incubated hPSC-CM with the lysosomal .
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.. inhibitor vacuolin-1 during mechanical stretch. As demonstrated
previously, mechanical stretch induced cathepsin D release into
the extracellular environment, whereas hPSC-CM incubated with
vacuolin-1 did not show increased levels of released cathepsin D
(Figure 4A). To assess the intracellular levels of cathepsin D protein,
western blot was performed and we observed increased levels of
intracellular cathepsin D after addition of vacuolin-1 (Figure 4B). As
cathepsin D may be essential for the induction of stress responses,
we investigated potential beneficial effects of vacuolin-1-mediated
cathepsin D retention by measuring levels of apoptosis, necrosis,
autophagy, and metabolism in stretched hPSC-CM with cathepsin
D knockdown. We observed that apoptosis and necrosis (Figure 4C
and 4D, respectively) were only marginally affected by the adminis-
tration of vacuolin-1, but the ability to induce autophagy could be
restored (Figure 4E). However, metabolic rates (i.e. cellular capac-
ity to convert a pre-luminescent substrate to luminescent signal)
remained unaffected by vacuolin-1 (Figure 4F).
Discussion
Our findings show that cathepsin D levels in patients with HF
are associated with more advanced disease and higher rates of
mortality and hospitalization for HF. Secondly, we found that
cathepsin D is released by hPSC-CM following cardiac stretch
in correspondence with troponin T release. Thirdly, silencing
cathepsin D resulted in elevated levels of troponin T, especially
following induced stress. These findings suggest that intracellular
cathepsin D is essential for cardiomyocyte survival, while circulating
cathepsin D levels are correlated to disease severity.
Elevated levels of most other cathepsins (i.e. CTSB, CTSF CTSK,
CTSL, CTSS, and CTSV) have been associated with cardiovascular
diseases,27–33 but this is the first study showing that circulating lev-
els of cathepsin D predict adverse outcomes in HF. In a human set-
ting, higher levels of cathepsin D were associated with an increased
risk of coronary events in the Malmö Diet and Cancer cardiovas-
cular cohort.13 Similarly to our findings, cathepsin D levels were
Figure 1 Cumulative incidence curves for the combined outcome of heart failure-related hospitalizations and/or all-cause mortality at 2 years
(A) and all-cause mortality at 2 years (B).
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Hazard ratios in predicting the combined endpoint (heart failure hospitalizations or all-cause mortality at
2 years)
Combined outcome All-cause mortality
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Univariable 1.38 (1.26–1.52) <0.001 1.46 (1.30–1.64) <0.001
Model 1 1.36 (1.24–1.49) <0.001 1.41 (1.26–1.59) <0.001
Model 2 1.31 (1.19–1.44) <0.001 1.40 (1.25–1.58) <0.001
Model 3 1.30 (1.19–1.43) <0.001 1.40 (1.24–1.58) <0.001
BIOSTAT-CHF risk model 1.12 (1.02–1.23) 0.016 1.15 (1.01–1.29) 0.028
CI, confidence interval; HR, hazard ratio.
Model 1 is adjusted for age and sex.
Model 2 is adjusted for model 1 + body mass index, country, history of hypertension, diabetes.
Model 3 is adjusted for model 2+ beta-blockers, angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist usage at baseline.
BIOSTAT-CHF risk model is adjusted for age, heart failure hospitalization in the year before inclusion, oedema, N-terminal pro-B-type natriuretic peptide, systolic blood
pressure, haemoglobin, high-density lipoprotein levels, serum sodium concentration, and failure to prescribe a beta-blocker.
Figure 2 Cathepsin D (CTSD) was released by human stem cell-derived cardiomyocytes in concert with troponin T. Extracellular levels of
CTSD were elevated after stretch (A), while intracellular levels were only reduced after tumour necrosis factor alpha (TNF𝛼) stimulation or
hypoxia (B). Damage marker release of troponin T was also increased by mechanical stretch (C). Graphs show results from three independent
experiments; *P< 0.05; **P< 0.01; ***P< 0.001 vs. unstimulated control human stem cell-derived cardiomyocytes unless otherwise indicated.
Statistical analysis was done with with a Kruskal–Wallis test followed by Dunn’s post-hoc test. HIF1𝛼, hypoxia-inducible factor 1 alpha.
associated with the presence of diabetes and other markers of the
metabolic syndrome.13 Furthermore, cathepsin D was associated
with atherogenesis and carotid intima–media thickness.34,35 Most
importantly, cathepsin D protein levels were found to be increased
in explanted failing hearts from patients with ischaemic heart
disease.11 In a separate study, Naseem et al.36 found that cathep-
sin D levels in patients with myocardial infarction were increased
7–20 h following myocardial infarction in concert with increased
plasma renin activity. This study demonstrated that angiotensino-
gen can be converted to angiotensin I by circulating cathepsin D and
thereby provides an alternative pathway to catalyse angiotensin II
formation post-myocardial infarction. A previous study by Bouwens
et al.37 found an association of cathepsin D with adverse outcomes
in 263 patients with chronic HF. We extend upon these previous
findings in several ways: (i) our study provides results on the clin-
ical correlates and prognostic value of cathepsin D in a large, well .
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.. characterized, multinational, prospective study with independent
validation; (ii) results of the present study show evidence support-
ing that active cardiac excretion of cathepsin D is associated with
adverse clinical outcomes.
A previous study byWu et al.11 investigated the role of cathepsin
D in ischaemic heart disease and observed a detrimental effect of
cathepsin D knockout. In their study, cathepsin D+/− mice displayed
reduced autophagic flux following myocardial infarction and a dias-
tolic dysfunction. Based on this study and on the ubiquitous expres-
sion of cathepsin D, we hypothesized that cathepsin D is essential
for cellular stress responses and coping mechanisms for cardiomy-
ocytes in order to survive and maintain adequate contractile func-
tion. To determine the specific effects of cathepsin D ablation in
hPSC-CM, we transduced hPSC-CM with a cathepsin D-specific
shRNA resulting in cathepsin D knockdown. We expected that
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Cathepsin D (CTSD) knockdown resulted in increased cell death following mechanical stretch. Intracellular levels of CTSD were
greatly reduced by shRNA-mediated CTSD gene silencing (A); extracellular levels were found to show a similar pattern (B). Troponin T levels
were found to be increased following mechanical stretch with CTSD knockdown (C). CTSD knockdown resulted in deteriorated sarcomeric
structure (D). Mechanical stretch induced apoptosis regardless of CTSD knockdown (E), whereas necrosis is increased after stretch in human
stem cell-derived cardiomyocytes (hPSC-CM) with CTSD knockdown (F). Stretching induced autophagy in scrambled control hPSC-CM, which
was abrogated in CTSD-deficient cells (G). Stretching resulted in increased metabolism in hPSC-CM with CTSD silencing exclusively (GH).
Graphs show results from three independent experiments; *P< 0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001 vs. static scrambled control
hPSC-CM (shSCR) unless otherwise indicated. Statistical analysis was done with with a Kruskal–Wallis test followed by Dunn’s post-hoc test.
severely reduced cathepsin D levels would induce cellular dam-
age due to aberrant proteolysis or protein accumulation (as seen
in neurodegenerative disorders).38 We observed increased levels
of troponin T in the cell medium of hPSC-CM with cathepsin D
knockdown (without mechanical stretch), indicating that cardiomy-
ocyte survival is reduced due to cathepsin D deficiency. Interest-
ingly, cathepsin D knockdown resulted in a striking increase of
extracellular troponin T levels following mechanical stretch, as well
as increased necrosis and impaired induction of autophagy. Inhibi-
tion of lysosomal exocytosis prevented active cathepsin D secre-
tion and retention of intracellular cathepsin D. While this restored
the ability of stressed hPSC-CM to induce autophagy, we argue
that general (and non-specific) inhibition of lysosomal exocytosis
may hamper stress-induced lysosomal-dependent coping mecha-
nisms that may be more important to cell survival compared to
increased levels of cathepsin D as a factor in autophagy. Addition-
ally, reduction of cathepsin D resulted in deteriorated sarcomeric
structures that may contribute to HF progression. Our data indi-
cate that cathepsin D is necessary for cardiomyocyte survival, espe-
cially during stress. These findings are in line with the previously
mentioned study by Wu et al.11 Moreover, apoptosis and necrosis
were significantly increased following cathepsin D silencing, while
stress-induced autophagy was abrogated. Combined, these results .
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. suggest that regulated cell death (i.e. apoptosis) is dependent on
autophagy as part of the stress response. Abrogated cathepsin
D function might, therefore, lead to uncontrolled cell death and
increased stress-induced metabolism.
The present study applied various methods to induce cellular
stress responses. Since mechanical stretch resulted in the highest
levels of cathepsin D in cell medium, we opted to continue with
this well characterized and representative cardiac stress model
to study the effects of cathepsin D knockdown (i.e. mechanical
stretch). Both the present study and the study by Wu et al. caused
cathepsin D deficiencies in cardiomyocytes and mice, respectively,
which has not yet been proven to be representative for HF patients.
It is clear that insufficient intracellular levels of cathepsin D are
detrimental for stress responses and subsequent cardiomyocyte
survival. We observed no differences in intracellular cathepsin
D levels after mechanical stretch, while extracellular levels were
significantly increased.
Limitations
Due to the relative nature of the methodology used to determine
biomarker levels, no absolute cathepsin D levels are known. As
a result, it is not possible to determine absolute thresholds that
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Inhibition of lysosomal exocytosis by vacuolin-1 improved autophagic response by retention of intracellular cathepsin D (CTSD).
Extracellular levels of CTSD after stretch were reduced compared to stretched vehicle control stem cell-derived cardiomyocytes (hPSC-CM)
(A). Incubation with vacuolin-1 increased intracellular levels of CTSD (B). Inhibition of CTSD secretion marginally affected apoptosis (C)
and prevented induction of necrosis (D). Autophagy was restored by vacuolin-1 in CTSD knockdown hPSC-CM after stretch (E), whereas
metabolism was unaffected (F). Graphs show results from three independent experiments; *P< 0.05; **P< 0.01 vs. static scrambled control
hPSC-CM (shSCR) unless otherwise indicated. Statistical analysis was done with with a Kruskal–Wallis test followed by Dunn’s post-hoc test.
can be used for prognostic purposes. Moreover, we cannot draw
any conclusions regarding the effects of abolished cathepsin D in
other cell types based on the experiments performed in this study.
Notably, Wu et al.11 studied the effects of cathepsin D in ablation in
global heterozygous knockout mice after coronary artery ligation.
Therefore, the observed effects in that study could also arise from
detrimental effects on other cell types, e.g. endothelial function
is closely associated with cardiomyocyte function. The observed
adverse effects on cardiac function in the study of Wu et al.
could have arisen from endothelial damage as opposed to direct
myocardial effects. It remains unknown whether patients with
high levels of circulating cathepsin D concurrently have reduced
intracellular levels of cathepsin D. However, it is not feasible to
determine intracellular cathepsin D levels in the heart at the time
of blood collection.
Finally, the validation cohort was slightly older with a higher
ejection fraction and lower B-type natriuretic peptide levels. This
is a limitation, because it might inflate the type II error, but
also a particular strength because the association of cathepsin D
with adverse clinical outcomes was shown in two independent
cohorts with slight differences in age, ejection fraction and disease
severity. .
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.. Conclusions
In patients with HF, higher circulating cathepsin D levels corre-
late with greater disease severity. Our in vitro studies suggest
that cathepsin D is secreted from hPSC-CM following hypoxia
and mechanical stretch and that cathepsin D is necessary for
(autophagy-mediated) human stem cell-derived cardiomyocyte sur-
vival, especially during stress.
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